TB Diagnosis: Tuberculin Skin Test, IGRA, Imaging, and Culture

Diagnosing TB requires different tests for latent infection versus active disease, and no single test is perfect — understanding each test's strengths and limitations helps patients understand what results mean and why doctors sometimes order several tests before reaching a conclusion.

Table of Contents

  1. The Diagnostic Framework: Latent vs Active TB
  2. Tuberculin Skin Test (TST / Mantoux Test)
  3. Interferon-Gamma Release Assays (QuantiFERON, T-SPOT)
  4. Chest X-Ray in TB Diagnosis
  5. Sputum Smear Microscopy and AFB Culture
  6. GeneXpert MTB/RIF and Molecular Testing
  7. Bronchoscopy and Biopsy for Difficult Cases
  8. Special Diagnostic Situations
  9. Research Papers
  10. Connections
  11. Featured Videos

The Diagnostic Framework: Latent vs Active TB

The most important concept in TB diagnostics is understanding that latent TB infection and active TB disease require completely different tests — and that confusing the two leads to misdiagnosis. These are not just different stages of the same condition; they are fundamentally different states requiring different diagnostic approaches.

Latent TB infection means the bacteria are present in the body but are being held in check by the immune system. The person has no symptoms, is not contagious, and the bacteria cannot be found in sputum or blood cultures. The only evidence of infection is the immune system's memory of having encountered TB antigens. This is why latent TB can only be detected through immune memory tests — the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs). These tests detect the immune response, not the bacteria themselves.

Active TB disease means the bacteria are actively multiplying and causing tissue damage. In pulmonary TB, bacteria are shed into the airways and can often be found in sputum. This is when direct tests for bacteria become useful — sputum smear microscopy, culture, and molecular tests like GeneXpert can detect the actual organism. A positive TST or IGRA in a person with symptoms does not diagnose active TB; it only tells you that the person was previously infected. You still need direct microbiological evidence to confirm active disease.

The clinical algorithm runs as two separate tracks. If a person has symptoms consistent with active TB — chronic cough, night sweats, unexplained weight loss, fever — the workup should start with tests for active disease: chest X-ray, sputum examination, and GeneXpert. Do not start with a TST or IGRA in a symptomatic person; a negative result would be misleading because both tests can be falsely negative in active TB, especially in immunocompromised patients where the immune response may be blunted.

If a person has no symptoms but belongs to a high-risk group — a recent close contact of an active TB case, someone with HIV, a healthcare worker, or a person who immigrated from a high-burden country — the workup should focus on latent TB with TST or IGRA. This is screening, not diagnosis of disease. A positive result in this scenario means treatment for latent TB is warranted, even without symptoms or radiographic abnormalities.

One critical nuance: a negative IGRA does not exclude active TB in immunocompromised people. HIV, chemotherapy, and biological immunosuppressants (TNF inhibitors, corticosteroids) can blunt the interferon-gamma response enough to produce a false-negative result. In these patients, clinical suspicion and direct microbiological testing matter more than immune-based tests.

Back to Table of Contents

Tuberculin Skin Test (TST / Mantoux Test)

The tuberculin skin test, also called the Mantoux test, has been the backbone of TB screening for over a century. Despite its limitations, it remains widely used because it is inexpensive, requires no laboratory equipment, and has been validated in enormous populations worldwide.

The procedure is straightforward. A healthcare worker injects 0.1 mL of purified protein derivative (PPD) — a standardized extract of M. tuberculosis antigens — into the inner surface of the forearm, just below the skin (intradermally). A correctly placed injection creates a small pale wheal (raised bump) 6–10 mm in diameter immediately after injection. The patient returns 48–72 hours later for the reading. Waiting fewer than 48 hours risks a false negative; waiting more than 72 hours risks the reaction having faded.

What the healthcare worker measures at the reading is the induration — the firm, palpable, raised area caused by immune cells accumulating at the injection site. Redness (erythema) around the site is noted but does not count toward the measurement. The induration is measured across its widest point perpendicular to the forearm's long axis, in millimeters.

The interpretation of results is not a single fixed cutoff. Different threshold sizes are used for different populations based on their risk of true infection versus the probability of a false positive. This tiered approach reflects the fact that the test's positive predictive value depends on how common TB is in the population being tested.

A reaction of 5 mm or more is considered positive in the highest-risk groups: people with HIV infection, people who have had recent close contact with an active TB case, people with organ transplants or on immunosuppressive therapy equivalent to 15 mg/day or more of prednisone for more than a month, and people with radiographic evidence of old healed TB. In these groups, even a small reaction should not be dismissed because the consequence of a missed latent TB that reactivates is serious.

A reaction of 10 mm or more is positive for people with intermediate risk factors: those born in or who lived in countries with high TB burden, current or former injection drug users, residents or employees of high-risk congregate settings (prisons, homeless shelters, nursing homes), healthcare workers who work with TB patients, children under 4, and people with medical conditions that increase the risk of reactivation (diabetes, silicosis, renal failure, head and neck cancers, low body weight).

A reaction of 15 mm or more is considered positive only for people with no identified risk factors for TB. In this population, the base rate of true latent TB infection is low, so a lower threshold would produce too many false positives.

The most important limitation of the TST is that it cannot distinguish between infection with M. tuberculosis and prior BCG vaccination. The BCG vaccine uses live attenuated Mycobacterium bovis, and because BCG shares many antigens with TB, people vaccinated with BCG will often mount a positive TST reaction even if they have never been infected with actual TB. This is a major problem in high-income countries screening immigrants from BCG-vaccinating countries — a positive TST in a BCG-vaccinated adult may be a false positive, but cannot be reliably distinguished from true infection without an IGRA.

The boosting effect is another important phenomenon in serial testing, particularly relevant in healthcare worker screening programs. In people with old TB infection whose immune response to PPD has waned, a first TST can stimulate the immune system and cause a stronger (falsely elevated) reaction to a second TST administered 1–3 weeks later. This can make it appear as though someone converted from negative to positive between two tests. Two-step testing — administering a second TST 1–3 weeks after the first — is used in healthcare workers at initial employment to establish a true baseline, so that later seroconversion (from a new infection) can be reliably identified as a real conversion rather than a boosted response.

The TST is also limited in immunocompromised patients. People with advanced HIV, malnutrition, overwhelming active TB (miliary TB), or severe illness may be unable to mount a detectable skin reaction even if truly infected — a phenomenon called cutaneous anergy. A negative TST in these patients cannot be reassuring.

Back to Table of Contents

Interferon-Gamma Release Assays (QuantiFERON, T-SPOT)

Interferon-gamma release assays (IGRAs) are blood tests developed in the early 2000s that largely overcome the BCG-vaccination limitation of the TST. They represent a significant advance in latent TB diagnostics, although they have their own set of limitations.

The underlying principle is elegant. A blood sample is drawn and the white blood cells (T lymphocytes) are exposed to TB-specific antigens in the laboratory — specifically ESAT-6 and CFP-10, two proteins encoded by a region of the M. tuberculosis genome called the Region of Difference 1 (RD1). Crucially, RD1 is absent from the BCG vaccine strain and from most non-tuberculous mycobacteria species that cause false-positive TSTs. If the person's T cells have previously encountered real M. tuberculosis, they will recognize these antigens and respond by secreting interferon-gamma. The test measures how much interferon-gamma is produced.

Two IGRAs are commercially available. QuantiFERON-TB Gold Plus (QFT-Plus) uses an enzyme-linked immunosorbent assay (ELISA) to measure total interferon-gamma levels in the blood. It reports a quantitative result in international units per mL, with a cutoff of 0.35 IU/mL distinguishing positive from negative. Results also include an indeterminate category for samples where the positive control (mitogen-stimulated tube) fails or the negative control (nil tube) is too high, suggesting either immune suppression or procedural problems. T-SPOT.TB takes a different approach: it uses an ELISPOT method that counts the number of individual T cells secreting interferon-gamma in response to the antigens, reporting the result as the number of "spots" on a membrane.

The key advantages of IGRAs over the TST are substantial. Because ESAT-6 and CFP-10 are not present in BCG, a positive IGRA in a BCG-vaccinated person is much more likely to represent true M. tuberculosis infection. IGRAs require only a single visit — the patient doesn't have to return 48–72 hours later for a reading. This dramatically improves completion rates in populations that are difficult to follow up. IGRAs are also more specific in low-incidence settings, meaning they produce fewer false positives.

However, IGRAs have their own limitations that are important to understand. Indeterminate results occur in up to 10–15% of immunocompromised patients — a frustrating outcome because these are often the highest-risk patients where the result matters most. The blood sample must be processed within a specific time window (typically within 8–16 hours of collection for QFT-Plus), which requires coordinated laboratory logistics and limits their use in remote or resource-limited settings. IGRAs are considerably more expensive than TSTs. They are not recommended as the primary test in children under 5 because the T cell response is less mature and results are less reliable.

Head-to-head comparisons between IGRAs and TST show roughly equivalent sensitivity for detecting latent TB in immunocompetent adults, with IGRAs having higher specificity (fewer false positives) in BCG-vaccinated populations. Neither test has been validated against a true gold standard for latent TB — by definition, you cannot culture latent bacteria — so sensitivity estimates come from studies in people with known active TB, known recent exposure, or people who subsequently developed active TB despite preventive therapy.

Current guidance from the CDC and WHO recommends IGRAs as the preferred test for BCG-vaccinated adults and for populations where follow-up for TST reading is unreliable. The TST remains acceptable and preferred for children under 5 years old, and either test is acceptable in most other situations. In high-risk populations, some guidelines recommend sequential testing (TST followed by IGRA, or vice versa) to reduce false negatives, treating a positive on either test as a positive overall.

Back to Table of Contents

Chest X-Ray in TB Diagnosis

The chest X-ray is often the first investigation that raises suspicion of active TB, and it remains an essential part of the diagnostic workup. An experienced radiologist reading a chest X-ray can often identify patterns strongly suggestive of TB — but the chest X-ray cannot by itself confirm the diagnosis. Microbiological confirmation is always required.

TB produces different radiographic patterns depending on whether this is a first-time infection (primary TB) or reactivation of latent disease (post-primary or reactivation TB), and depending on the patient's immune status.

Primary TB, which usually occurs in children or immune-naive adults experiencing their first TB exposure, typically appears as an area of air-space consolidation (an opacity indicating inflammation or fluid in the air sacs) in the lower or middle zones of the lungs, combined with enlarged hilar lymph nodes (the lymph nodes at the root of the lung where the airways branch). This combination — lung opacity plus prominent hilar lymphadenopathy — is called the primary complex or Ghon complex. Primary TB often resolves on its own in immune-competent people, leaving behind calcified scars (Ghon lesions) that can be seen on chest X-rays years later as evidence of old, healed infection.

Post-primary or reactivation TB in adults shows a dramatically different pattern that reflects the different immunological context. The hallmark is upper lobe predominance: infiltrates (areas of inflammation and consolidation) in the posterior segment of the upper lobes and the superior segment of the lower lobes. This upper lobe preference is thought to reflect the higher oxygen tension in the upper parts of the lungs, which favors M. tuberculosis growth. Thick-walled cavities are a classic and highly characteristic finding — these appear as areas of lucency (darker areas) within areas of consolidation, indicating that the center of the inflammatory mass has liquefied and drained into the airways. Satellite nodules — small nodular opacities surrounding a larger lesion — reflect local bronchogenic spread of disease.

Miliary TB produces a striking and alarming radiographic appearance: bilateral, symmetrical fine nodules measuring 1–2 mm distributed throughout both lungs, giving an appearance compared to millet seeds (hence the name). Miliary TB represents hematogenous dissemination of TB throughout the bloodstream and is a medical emergency requiring urgent treatment. It is more common in immunocompromised patients and young children.

Pleural effusion — fluid around the lung — can be the sole or predominant finding in TB pleuritis, particularly in younger patients. This typically causes blunting of one costophrenic angle on chest X-ray.

CT scanning of the chest is considerably more sensitive than plain chest X-ray for detecting early or subtle TB changes. CT can detect small cavities not visible on X-ray, hilar and mediastinal lymph node enlargement, and the "tree-in-bud" pattern — a branching nodular opacity in the peripheral airways that indicates endobronchial spread of infection and is highly suggestive of active infectious bronchiolitis, particularly TB.

A critical point that patients sometimes misunderstand: a completely normal chest X-ray does not rule out TB. Early pulmonary TB before significant tissue damage has occurred may have a normal X-ray. Extrapulmonary TB affecting lymph nodes, the spine, kidneys, or brain will not be visible on a chest X-ray at all. HIV-positive patients with very advanced immunosuppression can have active TB with a surprisingly unremarkable chest X-ray because the radiographic findings of TB (which are partly a product of the immune response to infection) are attenuated when the immune system is severely damaged. In all these situations, a normal chest X-ray should not terminate the diagnostic workup if clinical suspicion remains high.

Back to Table of Contents

Sputum Smear Microscopy and AFB Culture

Direct examination of sputum for acid-fast bacilli (AFB) has been the cornerstone of TB diagnosis in resource-limited settings for over 130 years. Despite being the oldest TB diagnostic technique, smear microscopy remains the most widely used test globally because it is fast, inexpensive, requires no electricity, and provides immediate actionable information about whether a person is infectious.

The Ziehl-Neelsen (ZN) staining technique exploits a unique property of mycobacteria: their cell walls contain a waxy lipid called mycolic acid that allows them to resist decolorization with acid alcohol after taking up a red dye (carbol fuchsin). This is why they are called "acid-fast" bacilli — they retain the red color after acid washing, while all other bacteria are decolorized and appear blue or colorless against the counterstain. The smear is positive when a trained microscopist sees the characteristic rod-shaped red bacilli under the microscope.

The major limitation of smear microscopy is its relatively low sensitivity. The test requires approximately 5,000–10,000 bacteria per milliliter of sputum to reliably detect them under the microscope. By contrast, liquid culture systems can detect as few as 10–100 organisms per mL. This means smear microscopy will miss approximately 40–60% of culture-positive pulmonary TB cases — the so-called smear-negative TB cases. This group includes early disease, patients co-infected with HIV (who tend to have lower bacterial loads), and patients with less severe immune responses producing less cavitation and sputum bacterial load.

Smear microscopy also cannot distinguish M. tuberculosis from the many non-tuberculous mycobacteria (NTM) that also stain acid-fast. A positive smear means "acid-fast bacilli seen" — not "M. tuberculosis confirmed." Culture and molecular testing are required to identify the species.

Specimen collection matters enormously for smear accuracy. The WHO recommends collecting two sputum specimens — early morning production tends to have the highest bacterial concentrations because secretions have accumulated overnight. If the patient cannot produce sputum spontaneously, induced sputum (inhaling nebulized hypertonic saline to trigger coughing) significantly improves yield. Three specimens were previously standard; current WHO guidance accepts two specimens in most settings without significant loss of diagnostic sensitivity when molecular tests are also being used.

Fluorescence microscopy using auramine-O stain on LED microscopes has largely replaced traditional ZN microscopy in well-resourced settings. The fluorescent stain makes AFB easier and faster to visualize (lower magnification covers more area per unit time) and increases sensitivity by approximately 10% compared to traditional ZN — it can detect organisms at lower concentrations. WHO recommends LED fluorescence microscopy as the preferred technique where available.

Culture is the gold standard for TB diagnosis and is required for all confirmed cases to determine drug susceptibility. Culture grows actual bacteria, allowing the laboratory to confirm M. tuberculosis as the species and to test which drugs will kill it. Two main culture methods exist. Solid media (Lowenstein-Jensen egg-based or Middlebrook agar) is inexpensive but slow — M. tuberculosis divides approximately every 16–24 hours, so colonies take 3–6 weeks to appear, and susceptibility testing on solid media takes another 3–4 weeks. Liquid media systems (BACTEC MGIT 960) detect bacterial growth by sensing oxygen consumption by a fluorescent sensor — growth appears in 2–3 weeks for smear-positive cases and 3–4 weeks for smear-negative cases, and drug susceptibility testing takes an additional 1–2 weeks. Liquid culture systems are more sensitive than solid media and are the preferred standard in high-income countries.

Back to Table of Contents

GeneXpert MTB/RIF and Molecular Testing

GeneXpert MTB/RIF, introduced in 2010 and endorsed by the WHO in 2011, was arguably the most important advance in TB diagnostics in decades. It transformed the diagnostic landscape by delivering results in 2 hours that previously required weeks of culture — and simultaneously detecting rifampicin resistance.

GeneXpert is a cartridge-based, real-time PCR (polymerase chain reaction) system that requires minimal training. The healthcare worker places sputum into a liquid reagent, loads the mixture into a single-use cartridge, and inserts it into the GeneXpert machine. The machine performs all subsequent steps automatically: cell lysis to release DNA, PCR amplification of M. tuberculosis-specific sequences in the rpoB gene (which encodes RNA polymerase), and detection. The system simultaneously probes for mutations in the 81-base pair "hot spot" region of rpoB where >95% of rifampicin resistance-conferring mutations cluster. A result — positive/negative for TB and susceptible/resistant/indeterminate for rifampicin — is available in approximately 100 minutes.

The WHO now recommends GeneXpert as the initial diagnostic test (replacing sputum smear microscopy) for all adults and children suspected of having TB in all settings, including low-income countries. This recommendation reflects the dramatic improvement in diagnostic accuracy that GeneXpert provides over smear microscopy.

Sensitivity of GeneXpert MTB/RIF is approximately 88% in smear-positive cases and 67% in smear-negative, culture-positive cases — compared to smear microscopy sensitivity of approximately 70% in smear-positive and essentially 0% in smear-negative cases (by definition). This means GeneXpert diagnoses a substantial proportion of patients who would have been missed by smear alone, reducing the period of undiagnosed infectiousness. Specificity is very high (>98%), meaning very few false positives.

GeneXpert can be applied to specimens beyond sputum. It has been validated for gastric aspirate (for children who cannot expectorate), lymph node biopsy tissue, cerebrospinal fluid, pleural fluid, urine, and other samples — making it invaluable in extrapulmonary TB where sputum is irrelevant. Sensitivity varies by specimen type and disease site, but even with lower sensitivity than in sputum, GeneXpert substantially outperforms smear microscopy on non-sputum specimens.

Rifampicin resistance detected by GeneXpert is a strong proxy for MDR-TB (multidrug-resistant TB, defined as resistance to both rifampicin and isoniazid). More than 95% of rifampicin-resistant strains are also isoniazid-resistant. A GeneXpert result showing rifampicin resistance should therefore trigger presumptive MDR-TB treatment while culture-based full drug susceptibility testing is awaited.

GeneXpert Ultra, the second-generation platform released in 2017, uses two sets of overlapping PCR targets and a larger detection chamber, increasing sensitivity to detect as few as 16 bacteria/mL — substantially lower than the original GeneXpert's limit of approximately 131 bacteria/mL. GeneXpert Ultra is particularly valuable for smear-negative, HIV-associated, and pediatric TB, where bacterial loads tend to be lower. One trade-off is slightly lower specificity compared to the original GeneXpert, particularly in specimens from people with a history of previously treated TB where non-viable DNA fragments can persist and produce "trace" positive results.

Important limitations of molecular tests: GeneXpert detects DNA, not live bacteria. A person who has completed successful TB treatment may remain GeneXpert-positive for weeks to months because bacterial DNA fragments persist even after all live organisms are killed. This means GeneXpert cannot reliably be used to monitor treatment response. Additionally, GeneXpert only probes for rifampicin resistance; full resistance profiling for other drugs (isoniazid, fluoroquinolones, injectable agents, and newer drugs) requires either line probe assays or whole genome sequencing. For patients with rifampicin-resistant TB, comprehensive resistance testing is essential to guide appropriate regimen selection.

Line probe assays (LPA), such as the Hain GenoType MTBDRplus and MTBDRsl, extend molecular resistance detection to isoniazid, fluoroquinolones, and injectable second-line drugs. Whole genome sequencing (WGS) — now becoming available in some national reference laboratories — provides comprehensive resistance profiling for all clinically relevant drugs and simultaneously enables phylogenetic analysis for outbreak investigation and transmission tracking.

Back to Table of Contents

Bronchoscopy and Biopsy for Difficult Cases

When standard non-invasive investigations — chest X-ray, sputum smear, GeneXpert — fail to yield a diagnosis in a patient with high clinical suspicion of TB, more invasive procedures become necessary. Bronchoscopy, tissue biopsy, and pleural procedures each play a role in specific diagnostic scenarios.

Bronchoscopy with bronchoalveolar lavage (BAL) is indicated when a patient cannot produce adequate sputum — which is common in patients with early TB, HIV-associated TB, or children, and in patients whose cough is non-productive. During bronchoscopy, a flexible tube is passed through the nose or mouth, down the trachea, and into the airways. Saline is instilled into a segment of lung and then aspirated back — this BAL fluid contains cells and organisms from the lower airways. GeneXpert, AFB smear, and mycobacterial culture can all be performed on BAL fluid, with sensitivity roughly comparable to induced sputum in most studies.

Transbronchial biopsy — using small forceps passed through the bronchoscope to take tiny pieces of lung tissue — can demonstrate the characteristic histological finding of TB: caseating granulomas. A granuloma is a cluster of immune cells (macrophages, epithelioid cells, Langerhans giant cells) organized around a focus of infection. "Caseating" refers to the central area of cell death that has a cheese-like consistency macroscopically — this pattern, while not unique to TB (sarcoidosis produces non-caseating granulomas), is highly characteristic when combined with clinical context. Tissue should be sent for both histopathology and mycobacterial culture simultaneously; never let the pathology laboratory use all available tissue for histology without reserving a portion for culture.

Endobronchial TB — TB involving the bronchial wall mucosa — can sometimes be directly visualized at bronchoscopy as mucosal irregularity, hyperemia, edema, or ulceration. Biopsies of visible abnormalities have high diagnostic yield in this situation.

CT-guided percutaneous needle biopsy is used for peripheral pulmonary nodules or masses not accessible by bronchoscopy. The radiologist uses CT fluoroscopy to guide a needle through the chest wall into the lesion under local anesthesia. Core biopsies provide more tissue than fine-needle aspiration and should be sent for both histology and culture.

Lymph node TB (lymph node tuberculosis, or TB lymphadenitis) is the most common form of extrapulmonary TB globally. Cervical lymph nodes are most commonly affected. Lymph node biopsy — either excisional (surgical removal of the whole node) or core needle biopsy — shows caseating granulomas and may grow M. tuberculosis on culture. Fine-needle aspiration cytology can sometimes show caseating material and occasional AFB on smear, but a negative fine-needle aspirate does not exclude TB — the sensitivity is considerably lower than core biopsy or excisional biopsy. For mediastinal lymphadenopathy, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) provides access to mediastinal nodes without surgical incision.

Pleural TB presents a particular diagnostic challenge because the pleural fluid itself is typically paucibacillary — very few bacteria are present. AFB smear on pleural fluid is positive in only approximately 5% of TB pleuritis cases. GeneXpert on pleural fluid has sensitivity of approximately 15–20%. Culture of pleural fluid is positive in 30–40% of cases. The best yield comes from closed pleural biopsy or video-assisted thoracoscopic surgery (VATS) pleural biopsy, which shows caseating pleural granulomas in over 80% of TB pleuritis cases. Pleural fluid adenosine deaminase (ADA) — an enzyme released by activated lymphocytes — is elevated in TB pleuritis (typically >40 U/L) and is a useful diagnostic marker when more invasive procedures are not immediately feasible.

Back to Table of Contents

Special Diagnostic Situations — Children, Extrapulmonary, and Point-of-Care

Several patient populations and disease presentations require modified diagnostic approaches because standard adult pulmonary TB algorithms do not translate directly to their situations.

Children present particular challenges because they rarely produce sputum — the cough in childhood TB tends to be non-productive and children swallow rather than expectorate secretions. Several alternative specimen collection strategies are used. Gastric aspirate is collected in the early morning before the child has eaten — a nasogastric tube is passed and stomach contents aspirated to recover swallowed overnight bronchial secretions. GeneXpert and culture on gastric aspirate have moderate sensitivity in childhood TB. Induced sputum uses nebulized 3–5% hypertonic saline followed by physiotherapy to promote productive coughing; this is feasible in children over 2 years in experienced centers. The string test (Entero-Test) involves the child swallowing a weighted capsule containing a nylon string; one end of the string hangs out of the mouth; 4–6 hours later the string is withdrawn and the bile-stained portion from the stomach is examined — this is less invasive than nasogastric aspiration for collecting gastric contents in children who cannot cooperate with tube insertion. Nasopharyngeal aspirate can also be used for GeneXpert and culture in very young children.

TB meningitis is a medical emergency with high mortality if treatment is delayed, yet it is diagnostically challenging because the bacterial load in CSF is extremely low. CSF AFB smear is positive in only approximately 20% of cases. CSF GeneXpert has a sensitivity of approximately 40–80% depending on the volume of CSF submitted and whether Ultra or standard cartridges are used — a higher volume of CSF (at least 3–4 mL, ideally more) substantially improves yield. CSF culture, while more sensitive than smear, requires weeks to become positive. CSF biochemistry in TB meningitis typically shows lymphocyte-predominant pleocytosis (elevated white cell count with mostly lymphocytes), high protein, and low glucose. Adenosine deaminase in CSF is less reliable than in pleural fluid but can provide supporting evidence.

Renal TB is often detected through early morning urine culture — the kidney can shed TB bacteria into urine when the renal parenchyma is infected. At least 3 early morning urine specimens should be collected for AFB smear, culture, and increasingly GeneXpert (though GeneXpert sensitivity on urine is variable). Intravenous urography or CT urography may show calyceal destruction or ureteral strictures characteristic of renal TB.

Pericardial TB causes pericardial effusion (fluid around the heart) and can progress to constrictive pericarditis — scarring of the pericardium that restricts heart filling — if untreated. Pericardial fluid ADA is elevated and supports the diagnosis. Pericardiocentesis (needle drainage) provides fluid for AFB smear, culture, and GeneXpert, but bacterial yield is low. Pericardial biopsy at surgery or video-assisted procedures shows caseating granulomas in most cases.

Spinal TB (Pott's disease) typically affects the vertebral body and intervertebral disc with collapse creating the characteristic "gibbus" deformity (kyphotic angulation). CT-guided biopsy of the affected vertebra provides tissue for histology and culture.

Urine lateral-flow lipoarabinomannan (LAM) test represents the most promising point-of-care diagnostic development in recent years specifically for a defined patient population. LAM is a cell wall component of M. tuberculosis shed into urine when bacteria are breaking down, particularly in the context of immune suppression. The Alere Determine TB LAM Ag lateral-flow test (AlereLAM) produces a result in 25 minutes on urine — no laboratory equipment needed. WHO has conditionally recommended AlereLAM specifically for HIV-positive adults with CD4 count below 100 cells/μL or those who are seriously ill, in settings of high TB prevalence. In this population the test has sensitivity of approximately 40–50% with high specificity. Critically, AlereLAM is not useful in HIV-negative patients or in HIV-positive patients with higher CD4 counts — sensitivity drops dramatically. Using it outside the recommended population leads to high rates of missed diagnoses.

The diagnostic algorithm for every special population ultimately follows the same principle: combine anatomically appropriate specimen collection, direct microbiological testing (smear, GeneXpert, culture on the relevant specimen), histopathology where tissue is available, and biochemical markers (ADA, protein, glucose in body fluids), assessed in the context of clinical presentation and epidemiological risk. No single test is sufficient — the diagnosis of TB in difficult presentations requires the integration of multiple imperfect pieces of evidence.

Back to Table of Contents

Research Papers

Back to Table of Contents

Connections

Back to Table of Contents